嵌合抗原受体 T 细胞在神经母细胞瘤小鼠模型中的临床前试验。

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

STAR Protoc. 2021 Nov 10;2(4):100942. doi: 10.1016/j.xpro.2021.100942. eCollection 2021 Dec 17.

The translation of chimeric antigen receptor (CAR) T cell therapy for pediatric solid tumors is limited by the lack of preclinical models that fully recapitulate solid tumor biology. We describe steps to implement neuroblastoma metastatic and orthotopic mouse models. We delineate an analysis pipeline to quantify the efficacy and determine the immunological characteristics of both CAR T and tumor cells in these models. Both mouse models can be applied to evaluate other experimental therapies for neuroblastoma. For complete details on the use and execution of this protocol, please refer to Li et al. (2021).

嵌合抗原受体 (CAR) T 细胞疗法在儿科实体瘤中的应用受到缺乏充分模拟实体瘤生物学的临床前模型的限制。我们描述了实施神经母细胞瘤转移和原位小鼠模型的步骤。我们描述了一个分析管道，用于量化这些模型中 CAR T 细胞和肿瘤细胞的疗效，并确定其免疫学特征。这两种小鼠模型都可用于评估神经母细胞瘤的其他实验疗法。有关该方案的使用和实施的完整详细信息，请参阅 Li 等人。（2021 年）。